AbbVie has filed a lawsuit against the U.S. government, seeking clearer guidance on patients eligible for a drug discount program.

AbbVie (ABBV) executes an excellent portfolio renewal beyond Humira's patent expiry, with Skyrizi and Rinvoq delivering robust double-digit revenue gains. Their efficient R&D and successful M&A activities have enabled a resilient pipeline, with these developments contributing to their renewed, accelerated profitable growth trends over the next few years. Despite the lowered FY2026 EPS guidance to $14.06, their underlying adjusted figures remain stable, with near-term headwinds merely attributed to lumpy IPR&D and milestone expenses.

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

AbbVie, Novo Nordisk, and Verizon Communications are stellar dividend stocks with strong financials. These stocks pay between 3.4% and 5.8% in dividends.

Applications Are Open Now Through April 29 for Entrepreneurs to Apply and Further Unlock Their Potential. Since 2023, the Brand Has Awarded $1.2M to Grant Winners to Boost Their Businesses.

AbbVie remains a buy, as recent EPS guidance reductions are driven by normal IPR&D and milestone expenses, not operational weakness. Their Q4 showed robust 10% revenue growth and a 38.3% adjusted operating margin, with bottom-line growth outpacing sales. Pipeline strength is evident with positive Skyrizi and ABBV-295 trial results, offsetting competitive and regulatory headwinds.

AbbVie has successfully navigated through a major patent cliff, enabling it to sustain a dividend growth streak for more than a decade. Thanks to two strong product portfolios, AbbVie's underlying growth, dividend growth, and share price growth are likely to persist.

AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204.

More than 300,000 Americans use a medication called Humira. Most of them are paying far too much for it.

The Allergan Medical Institute (AMI) Austin location strengthens the national training network with comprehensive, hands-on education. The Orange County and Atlanta AMI centers continue delivering best-in-class, expert-led aesthetics training focused on improving the treatment experience for patients.